Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.21B | 2.46B | 2.35B | 2.25B | 2.09B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.21B | 2.46B | 2.35B | 2.25B | 2.09B |
| Cost of Revenue | 516.97M | 402.72M | 328.44M | 323.37M | 306.41M |
| Gross Profit | 2.69B | 2.06B | 2.02B | 1.92B | 1.79B |
| SG&A Expenses | 1.18B | 1.08B | 1.00B | 975.53M | 878.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.95B | 2.64B | 2.46B | 2.43B | 2.28B |
| Operating Income | 264.70M | -180.19M | -115.37M | -176.89M | -188.13M |
| Income Before Tax | -31.94M | -379.58M | -355.38M | -377.38M | -321.10M |
| Income Tax Expenses | -75.51M | -60.49M | -85.68M | -99.22M | 11.16M |
| Earnings from Continuing Operations | 43.57 | -319.09 | -269.70 | -278.16 | -332.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.57M | -319.09M | -269.70M | -278.16M | -332.26M |
| EBIT | 264.70M | -180.19M | -115.37M | -176.89M | -188.13M |
| EBITDA | 321.02M | -123.69M | -57.82M | -120.22M | -132.15M |
| EPS Basic | 0.31 | -2.47 | -2.09 | -2.17 | -2.62 |
| Normalized Basic EPS | 0.03 | -1.82 | -1.70 | -1.82 | -1.57 |
| EPS Diluted | 0.24 | -2.47 | -2.10 | -2.17 | -2.62 |
| Normalized Diluted EPS | -0.03 | -1.82 | -1.70 | -1.82 | -1.57 |
| Average Basic Shares Outstanding | 520.87M | 518.01M | 514.12M | 510.58M | 507.07M |
| Average Diluted Shares Outstanding | 526.77M | 518.01M | 514.12M | 510.58M | 507.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |